Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma

Grace Kong, Michael S Hofman, William K Murray, Sharyn Wilson, Paul Wood, Peter Downie, Leanne Super, Annette Hogg, Peter Eu, Rodney John Hicks

Research output: Contribution to journalArticleResearchpeer-review

39 Citations (Scopus)

Abstract

Rationale: Pediatric patients with refractory neuroblastoma have limited therapeutic options. Neuroblastoma may express somatostatin receptors (SSTRs) allowing imaging with 68Ga-DOTA-Octreotate (GaTATE) positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT). We reviewed our experience with this theranostic combination. Materials and Methods: GaTATE studies (8 patients; 2 to 9 years old) were reviewed and compared with 123I-MIBG or posttreatment 131I-MIBG studies. Immunohistochemistry (IHC) for SSTR subtype 2 was performed in 5 patients. Four patients received PRRT. Results: GaTATE PET showed additional disease in 38% (3/8 patients), and upstaged 1 patient by detecting marrow involvement. IHC detected SSTR 2 in all patients assessed. Six patients were deemed suitable for PRRT on imaging. Four patients received 17 cycles of palliative PRRT (10 111In-DOTATATE; 5 177Lu-DOTATATE; 1 combined 111In and 177Lu-DOTATATE; 1 combined 177Lu and 90Y-DOTATATE) with no significant toxicity attributed to PRRT. All had objective responses. Two survivors are now 40 and 56 months from PRRT commencement. Conclusions: GaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging. PRRT seems safe, feasible, with responses observed in patients with progression despite multimodality treatment. These data support ongoing clinical trials in such patients.

Original languageEnglish
Pages (from-to)87-96
Number of pages10
JournalJournal of Pediatric Hematology Oncology
Volume38
Issue number2
DOIs
Publication statusPublished - 2016

Keywords

  • DOTATATE
  • Ga-68
  • Immunohistochemistry
  • Neuroblastoma
  • Peptide receptor
  • PET
  • Radionuclide therapy

Cite this

Kong, Grace ; Hofman, Michael S ; Murray, William K ; Wilson, Sharyn ; Wood, Paul ; Downie, Peter ; Super, Leanne ; Hogg, Annette ; Eu, Peter ; Hicks, Rodney John. / Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. In: Journal of Pediatric Hematology Oncology. 2016 ; Vol. 38, No. 2. pp. 87-96.
@article{44d2182ce1904045b3d13780f1347051,
title = "Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma",
abstract = "Rationale: Pediatric patients with refractory neuroblastoma have limited therapeutic options. Neuroblastoma may express somatostatin receptors (SSTRs) allowing imaging with 68Ga-DOTA-Octreotate (GaTATE) positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT). We reviewed our experience with this theranostic combination. Materials and Methods: GaTATE studies (8 patients; 2 to 9 years old) were reviewed and compared with 123I-MIBG or posttreatment 131I-MIBG studies. Immunohistochemistry (IHC) for SSTR subtype 2 was performed in 5 patients. Four patients received PRRT. Results: GaTATE PET showed additional disease in 38{\%} (3/8 patients), and upstaged 1 patient by detecting marrow involvement. IHC detected SSTR 2 in all patients assessed. Six patients were deemed suitable for PRRT on imaging. Four patients received 17 cycles of palliative PRRT (10 111In-DOTATATE; 5 177Lu-DOTATATE; 1 combined 111In and 177Lu-DOTATATE; 1 combined 177Lu and 90Y-DOTATATE) with no significant toxicity attributed to PRRT. All had objective responses. Two survivors are now 40 and 56 months from PRRT commencement. Conclusions: GaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging. PRRT seems safe, feasible, with responses observed in patients with progression despite multimodality treatment. These data support ongoing clinical trials in such patients.",
keywords = "DOTATATE, Ga-68, Immunohistochemistry, Neuroblastoma, Peptide receptor, PET, Radionuclide therapy",
author = "Grace Kong and Hofman, {Michael S} and Murray, {William K} and Sharyn Wilson and Paul Wood and Peter Downie and Leanne Super and Annette Hogg and Peter Eu and Hicks, {Rodney John}",
year = "2016",
doi = "10.1097/MPH.0000000000000411",
language = "English",
volume = "38",
pages = "87--96",
journal = "Journal of Pediatric Hematology Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. / Kong, Grace; Hofman, Michael S; Murray, William K; Wilson, Sharyn; Wood, Paul; Downie, Peter; Super, Leanne; Hogg, Annette; Eu, Peter; Hicks, Rodney John.

In: Journal of Pediatric Hematology Oncology, Vol. 38, No. 2, 2016, p. 87-96.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma

AU - Kong, Grace

AU - Hofman, Michael S

AU - Murray, William K

AU - Wilson, Sharyn

AU - Wood, Paul

AU - Downie, Peter

AU - Super, Leanne

AU - Hogg, Annette

AU - Eu, Peter

AU - Hicks, Rodney John

PY - 2016

Y1 - 2016

N2 - Rationale: Pediatric patients with refractory neuroblastoma have limited therapeutic options. Neuroblastoma may express somatostatin receptors (SSTRs) allowing imaging with 68Ga-DOTA-Octreotate (GaTATE) positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT). We reviewed our experience with this theranostic combination. Materials and Methods: GaTATE studies (8 patients; 2 to 9 years old) were reviewed and compared with 123I-MIBG or posttreatment 131I-MIBG studies. Immunohistochemistry (IHC) for SSTR subtype 2 was performed in 5 patients. Four patients received PRRT. Results: GaTATE PET showed additional disease in 38% (3/8 patients), and upstaged 1 patient by detecting marrow involvement. IHC detected SSTR 2 in all patients assessed. Six patients were deemed suitable for PRRT on imaging. Four patients received 17 cycles of palliative PRRT (10 111In-DOTATATE; 5 177Lu-DOTATATE; 1 combined 111In and 177Lu-DOTATATE; 1 combined 177Lu and 90Y-DOTATATE) with no significant toxicity attributed to PRRT. All had objective responses. Two survivors are now 40 and 56 months from PRRT commencement. Conclusions: GaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging. PRRT seems safe, feasible, with responses observed in patients with progression despite multimodality treatment. These data support ongoing clinical trials in such patients.

AB - Rationale: Pediatric patients with refractory neuroblastoma have limited therapeutic options. Neuroblastoma may express somatostatin receptors (SSTRs) allowing imaging with 68Ga-DOTA-Octreotate (GaTATE) positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT). We reviewed our experience with this theranostic combination. Materials and Methods: GaTATE studies (8 patients; 2 to 9 years old) were reviewed and compared with 123I-MIBG or posttreatment 131I-MIBG studies. Immunohistochemistry (IHC) for SSTR subtype 2 was performed in 5 patients. Four patients received PRRT. Results: GaTATE PET showed additional disease in 38% (3/8 patients), and upstaged 1 patient by detecting marrow involvement. IHC detected SSTR 2 in all patients assessed. Six patients were deemed suitable for PRRT on imaging. Four patients received 17 cycles of palliative PRRT (10 111In-DOTATATE; 5 177Lu-DOTATATE; 1 combined 111In and 177Lu-DOTATATE; 1 combined 177Lu and 90Y-DOTATATE) with no significant toxicity attributed to PRRT. All had objective responses. Two survivors are now 40 and 56 months from PRRT commencement. Conclusions: GaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging. PRRT seems safe, feasible, with responses observed in patients with progression despite multimodality treatment. These data support ongoing clinical trials in such patients.

KW - DOTATATE

KW - Ga-68

KW - Immunohistochemistry

KW - Neuroblastoma

KW - Peptide receptor

KW - PET

KW - Radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=84959386661&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000411

DO - 10.1097/MPH.0000000000000411

M3 - Article

VL - 38

SP - 87

EP - 96

JO - Journal of Pediatric Hematology Oncology

JF - Journal of Pediatric Hematology Oncology

SN - 1077-4114

IS - 2

ER -